TXN - Tracking Christopher Davis' Davis Selected Advisers 13F Portfolio - Q1 2025 Update
2025-05-13 20:09:29 ET
Summary
- Davis Selected Advisers’ 13F portfolio value increased to $17.35B with number of holdings rising from 100 to 104.
- Significant stake increases were noted in CVS Health, Applied Materials, Markel Corp, US Bancorp, MGM Resorts, Humana, Alphabet, Viatris, Cigna, Texas Instruments, Solventum, Trip.com, and Tyson Foods.
- Major stake reductions occurred in Capital One, Berkshire Hathaway, Meta Platforms, Amazon, Wells Fargo, Teck Resources, Quest Diagnostics, Owens Corning, Bank of New York Mellon, and JP Morgan Chase.
- The flagship Davis New York Venture Fund has outperformed the S&P 500 since 1969, achieving 11.45% annualized returns compared to the S&P 500’s 10.48%.
This article is part of a series that provides an ongoing analysis of the changes made to Davis Selected Advisers’ 13F portfolio on a quarterly basis. It is based on their regulatory 13F Form filed on 05/12/2025. Please visit our Tracking Christopher Davis’ Davis Selected Advisers 13F Portfolio series to get an idea of their investment philosophy and our previous update for the fund’s moves during Q4 2024....
Tracking Christopher Davis' Davis Selected Advisers 13F Portfolio - Q1 2025 Update